PMID- 38242039
OWN - NLM
STAT- MEDLINE
DCOM- 20240208
LR  - 20240208
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 171
DP  - 2024 Feb
TI  - HIF-1alpha serves as a co-linker between AD and T2DM.
PG  - 116158
LID - S0753-3322(24)00039-8 [pii]
LID - 10.1016/j.biopha.2024.116158 [doi]
AB  - Alzheimer's disease (AD)-related brain deterioration is linked to the type 2 
      diabetes mellitus (T2DM) features hyperglycemia, hyperinsulinemia, and insulin 
      resistance. Hypoxia as a common risk factor for both AD and T2DM. 
      Hypoxia-inducible factor-1 alpha (HIF-1alpha) acts as the main regulator of the 
      hypoxia response and may be a key target in the comorbidity of AD and T2DM. 
      HIF-1alpha expression is closely related to hyperglycemia, insulin resistance, and 
      inflammation. Tissue oxygen consumption disrupts HIF-1alpha homeostasis, leading to 
      increased reactive oxygen species levels and the inhibition of insulin receptor 
      pathway activity, causing neuroinflammation, insulin resistance, abnormal Abeta 
      deposition, and tau hyperphosphorylation. HIF-1alpha activation also leads to the 
      deposition of Abeta by promoting the abnormal shearing of amyloid precursor protein 
      and inhibiting the degradation of Abeta, and it promotes tau hyperphosphorylation by 
      activating oxidative stress and the activation of astrocytes, which further 
      exasperates AD. Therefore, we believe that HIF-alpha has great potential as a target 
      for the treatment of AD. Importantly, the intracellular homeostasis of HIF-1alpha is 
      a more crucial factor than its expression level.
CI  - Copyright (c) 2024 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Hai, Yang
AU  - Hai Y
AD  - Scientific Research and Experimental Center, Gansu University of Chinese 
      Medicine, Lanzhou 730000, Gansu Province, PR China; Key Laboratory of Dunhuang 
      Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, 
      PR China. Electronic address: cathyhaiyang@163.com.
FAU - Ren, Ke
AU  - Ren K
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Zhang, Yarong
AU  - Zhang Y
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Yang, Lili
AU  - Yang L
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Cao, Haoshi
AU  - Cao H
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Yuan, Xianxia
AU  - Yuan X
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Su, Linling
AU  - Su L
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China.
FAU - Li, Hailong
AU  - Li H
AD  - The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou 
      730000, Gansu Province, PR China.
FAU - Feng, Xiaoli
AU  - Feng X
AD  - Scientific Research and Experimental Center, Gansu University of Chinese 
      Medicine, Lanzhou 730000, Gansu Province, PR China; Key Laboratory of Dunhuang 
      Medicine, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu Province, 
      PR China.
FAU - Liu, Dongling
AU  - Liu D
AD  - School of Pharmacy, Gansu University of Chinese Medicine, Lanzhou 730000, Gansu 
      Province, PR China; Northwest Collaborative Innovation Center for Traditional 
      Chinese Medicine, Lanzhou 730000, Gansu Province, PR China; Gansu Pharmaceutical 
      Industry Innovation Research Institute, Lanzhou 730000, Gansu Province, PR China. 
      Electronic address: dongling83@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240118
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Hypoxia-Inducible Factor 1, alpha Subunit)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/metabolism
MH  - *Insulin Resistance
MH  - *Diabetes Mellitus, Type 2
MH  - Hypoxia
MH  - *Hyperglycemia
MH  - Hypoxia-Inducible Factor 1, alpha Subunit
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Hypoxia
OT  - Hypoxia-inducible factor-1 alpha
OT  - Type 2 diabetes
COIS- Declaration of Competing Interest No potential conflict of interest was reported 
      by the authors.
EDAT- 2024/01/20 05:42
MHDA- 2024/02/08 06:42
CRDT- 2024/01/19 18:15
PHST- 2023/09/24 00:00 [received]
PHST- 2023/12/27 00:00 [revised]
PHST- 2024/01/11 00:00 [accepted]
PHST- 2024/02/08 06:42 [medline]
PHST- 2024/01/20 05:42 [pubmed]
PHST- 2024/01/19 18:15 [entrez]
AID - S0753-3322(24)00039-8 [pii]
AID - 10.1016/j.biopha.2024.116158 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2024 Feb;171:116158. doi: 10.1016/j.biopha.2024.116158. Epub 
      2024 Jan 18.